Wang Lei, Zhang Li, Pan Haobo, Peng Songlin, Lv Minmin, Lu William Weijia
Center for Human Tissues and Organs Degeneration, Shenzhen Institute of Advanced Technology, Chinese Academy of Science, 1068 Xueyuan Avenue, 518055 Shenzhen, China.
BMC Musculoskelet Disord. 2014 Sep 27;15:319. doi: 10.1186/1471-2474-15-319.
The precise etiology of knee osteoarthritis (KOA) pain remains highly controversial and there is no known effective treatment. Due to the known and suggested effects of neuropeptide Y (NPY) on pain, we have sought to investigate the relationship between the concentration of NPY in synovial fluid of knee, pain of KOA, and structural severity of KOA.
One hundred KOA patients and twenty healthy participants (control group) were recruited. The pain and the radiographic grade of KOA were assessed separately by Hideo Watanabe's pain score and Tomihisa Koshino's scoring system. Synovial fluid of knee from all participants was collected with arthrocentesis. Radioimmunoassay was used to examine the concentration of NPY in synovial fluid of knee.
Concentrations of NPY in synovial fluid were significantly higher in KOA patients (124.7 ± 33.4 pg/mL) compared with controls (64.8 ± 26.3 pg/mL) (p = 0.0297). According to Hideo Watanabe's pain score, 100 KOA patients were divided into 5 subgroups: no pain (n = 12), mild pain (n = 25), moderate pain (n = 37), strong pain (n = 19) and severe pain (n = 7). Within the KOA group, significantly higher concentrations of NPY were found in each subgroup as pain intensified (no pain 81.4 ± 11.7 pg/mL, mild pain 99.1 ± 23.2 pg/mL, moderate pain 119.9 ± 31.5 pg/mL, strong pain 171.2 ± 37.3 pg/mL and severe pain 197.3 ± 41.9 pg/mL). Meanwhile, according to Tomihisa Koshino's scoring system, 100 KOA patients were divided into 3 subgroups: early stage (n = 30), middle stage (n = 53), advanced stage (n = 17). Concentrations of NPY in middle and advanced stage groups of KOA patients were significant higher than early stage group of KOA patients (early stage 96.4 ± 27.1 pg/mL, middle stage 153.3 ± 16.9 pg/mL, advanced stage 149.5 ± 36.7 pg/mL) (p = 0.0163, p = 0.0352). Concentrations of NPY in advanced stage group of KOA patients has no significant difference compare with middle stage group of KOA patients (p = 0. 2175).
This study demonstrated the presence and variation of concentrations of NPY in the KOA joint fluid, suggesting a role for NPY as a putative regulator of pain transmission and perception in KOA pain.
膝关节骨关节炎(KOA)疼痛的确切病因仍极具争议,且尚无已知的有效治疗方法。鉴于神经肽Y(NPY)对疼痛已知的和推测的作用,我们试图研究膝关节滑液中NPY浓度、KOA疼痛与KOA结构严重程度之间的关系。
招募了100例KOA患者和20名健康参与者(对照组)。通过渡边英夫疼痛评分和小筱富久评分系统分别评估KOA的疼痛和影像学分级。通过关节穿刺收集所有参与者的膝关节滑液。采用放射免疫分析法检测膝关节滑液中NPY的浓度。
KOA患者滑液中NPY浓度(124.7±33.4 pg/mL)显著高于对照组(64.8±26.3 pg/mL)(p = 0.0297)。根据渡边英夫疼痛评分,将100例KOA患者分为5个亚组:无疼痛(n = 12)、轻度疼痛(n = 25)、中度疼痛(n = 37)、重度疼痛(n = 19)和极重度疼痛(n = 7)。在KOA组内,随着疼痛加剧,各亚组中NPY浓度显著升高(无疼痛81.4±11.7 pg/mL,轻度疼痛99.1±23.2 pg/mL,中度疼痛119.9±31.5 pg/mL,重度疼痛171.2±37.3 pg/mL,极重度疼痛197.3±41.9 pg/mL)。同时,根据小筱富久评分系统,将100例KOA患者分为3个亚组:早期(n = 30)、中期(n = 53)、晚期(n = 17)。KOA患者中期和晚期组的NPY浓度显著高于早期组(早期96.4±27.1 pg/mL,中期153.3±16.9 pg/mL,晚期149.5±36.7 pg/mL)(p = 0.0163,p = 0.0352)。KOA患者晚期组的NPY浓度与中期组相比无显著差异(p = 0.2175)。
本研究证实了KOA关节液中NPY浓度的存在及变化,提示NPY在KOA疼痛中作为疼痛传递和感知的假定调节因子发挥作用。